Exhaled Nitric Oxide and Exhaled Breath Temperature as Potential Biomarkers in Patients with Pulmonary Hypertension

Table 3

FENO, CANO, and EBT data of all patients with pulmonary hypertension and compared among groups (ANOVA).

		Mean(SD)           Median (min-max)
		All patients
FENO50 ppb		11.9 (7.6)             10 (2.2-27.6)
CANO ppb		14.1 (9.7)             12.6 (3-41)
EBT °C		30.7 (1.4)             30.9 (27.9 – 33.2)
	Group A (PAH)	Group B (COPD)	Group C (HF)	p
FENO50	9.9 (5.7)	15.0 (9.3)	8.5 (5.2)
	10 (2.8-20.9)	11.8 (2.2-27.6)	8.0 (3.5-14)	0.271
CANO	16.9 (12.6)	13.9 (6.8)	6.7 (2.0)
	12.6 (6-41)	13.0 (3-28)	6.3 (5-9)	<0.045
EBT	30.9 (1.3)	31.2 (1.2)	29.0 (1.3)	<0.041
	30.9 (29.1-33.2)	31.4 (29.2-33.1)	28.5 (27.9-30.5)

Data reported as mean (standard deviation) and median (minimum-maximum).
FENO50: fractional exhaled nitric oxide at expiratory flow 50 ml/sec; CANO: alveolar concentration of nitric oxide; EBT: exhaled breath temperature; PAH: pulmonary arterial hypertension; COPD: chronic obstructive pulmonary disease; n.s.: not significant; and p: p value among the groups studied (ANOVA).